BACKGROUND: Dendritic cells (DC) have a role in the regulation of immunity and tolerance, attracting inflammatory cells by the production of various chemokines (CK). Fc gamma receptors (Fc gamma R) may be involved in regulation of the DC function. OBJECTIVE: To assess the expression of CK by immature (iDC) and mature DC (mDC) and its regulation by Fc gamma R in patients with RA and healthy donors (HC). METHODS: Expression of CK by DC from patients with RA and from HC was determined by real time quantitative PCR and ELISA. DC were derived from monocytes following standardised protocols. To study the potential regulation by Fc gamma R, iDC were stimulated with immune complexes (IC) during lipopolysaccharide (LPS) induced maturation. The presence of CK was studied in synovial tissue from patients with RA, osteoarthritis, and healthy subjects by RT-PCR and immunohistochemistry. RESULTS: iDC from patients with RA had markedly increased mRNA levels of the CK CCL18 and CXCL8. Upon maturation with LPS, expression of CCL18, CCL19, CXCL8, CCL3, and CCL17 increased dramatically, reaching significantly higher levels in patients with RA. Monocytes failed to express these CK, except for CXCL8 and CCL3. IC-mediated triggering of the Fc gamma R on DC from patients with highly active RA down regulated all CK, whereas the reverse was seen when DC from patients with low disease activity and healthy donors were stimulated. CCL18 was significantly increased in RA synovial tissue. CONCLUSION: Increased CK expression by DC was found in patients with RA. This expression is partly regulated by Fc gamma R triggering and results in an inhibitory DC subtype in RA upon Fc gamma R-mediated triggering.
BACKGROUND: Dendritic cells (DC) have a role in the regulation of immunity and tolerance, attracting inflammatory cells by the production of various chemokines (CK). Fc gamma receptors (Fc gamma R) may be involved in regulation of the DC function. OBJECTIVE: To assess the expression of CK by immature (iDC) and mature DC (mDC) and its regulation by Fc gamma R in patients with RA and healthy donors (HC). METHODS: Expression of CK by DC from patients with RA and from HC was determined by real time quantitative PCR and ELISA. DC were derived from monocytes following standardised protocols. To study the potential regulation by Fc gamma R, iDC were stimulated with immune complexes (IC) during lipopolysaccharide (LPS) induced maturation. The presence of CK was studied in synovial tissue from patients with RA, osteoarthritis, and healthy subjects by RT-PCR and immunohistochemistry. RESULTS: iDC from patients with RA had markedly increased mRNA levels of the CK CCL18 and CXCL8. Upon maturation with LPS, expression of CCL18, CCL19, CXCL8, CCL3, and CCL17 increased dramatically, reaching significantly higher levels in patients with RA. Monocytes failed to express these CK, except for CXCL8 and CCL3. IC-mediated triggering of the Fc gamma R on DC from patients with highly active RA down regulated all CK, whereas the reverse was seen when DC from patients with low disease activity and healthy donors were stimulated. CCL18 was significantly increased in RA synovial tissue. CONCLUSION: Increased CK expression by DC was found in patients with RA. This expression is partly regulated by Fc gamma R triggering and results in an inhibitory DC subtype in RA upon Fc gamma R-mediated triggering.
Authors: G J Adema; F Hartgers; R Verstraten; E de Vries; G Marland; S Menon; J Foster; Y Xu; P Nooyen; T McClanahan; K B Bacon; C G Figdor Journal: Nature Date: 1997-06-12 Impact factor: 49.962
Authors: A Regnault; D Lankar; V Lacabanne; A Rodriguez; C Théry; M Rescigno; T Saito; S Verbeek; C Bonnerot; P Ricciardi-Castagnoli; S Amigorena Journal: J Exp Med Date: 1999-01-18 Impact factor: 14.307
Authors: M C Dieu; B Vanbervliet; A Vicari; J M Bridon; E Oldham; S Aït-Yahia; F Brière; A Zlotnik; S Lebecque; C Caux Journal: J Exp Med Date: 1998-07-20 Impact factor: 14.307
Authors: Heidi S Schultz; Louise M Nitze; Louise H Zeuthen; Pernille Keller; Albrecht Gruhler; Jesper Pass; Jianhe Chen; Li Guo; Andrew J Fleetwood; John A Hamilton; Martin W Berchtold; Svetlana Panina Journal: J Immunol Date: 2015-02-27 Impact factor: 5.422
Authors: T R D J Radstake; A W T van Lieshout; P L C M van Riel; W B van den Berg; G J Adema Journal: Ann Rheum Dis Date: 2005-05-05 Impact factor: 19.103
Authors: Antonia Wimmer; Sophia K Khaldoyanidi; Martin Judex; Naira Serobyan; Richard G Discipio; Ingrid U Schraufstatter Journal: Blood Date: 2006-08-03 Impact factor: 22.113
Authors: David W Rosenthal; James A DeVoti; Bettie M Steinberg; Allan L Abramson; Vincent R Bonagura Journal: Mol Med Date: 2012-12-06 Impact factor: 6.354
Authors: Andrew D Cook; Ming-Chin Lee; Reem Saleh; Hsu-Wei Khiew; Anne D Christensen; Adrian Achuthan; Andrew J Fleetwood; Derek C Lacey; Julia E Smith; Irmgard Förster; John A Hamilton Journal: JCI Insight Date: 2018-03-22
Authors: A W T van Lieshout; P Barrera; R L Smeets; G J Pesman; P L C M van Riel; W B van den Berg; T R D J Radstake Journal: Ann Rheum Dis Date: 2004-07-15 Impact factor: 19.103
Authors: M Anthony Moody; Hua-Xin Liao; S Munir Alam; Richard M Scearce; M Kelly Plonk; Daniel M Kozink; Mark S Drinker; Ruijun Zhang; Shi-Mao Xia; Laura L Sutherland; Georgia D Tomaras; Ian P Giles; John C Kappes; Christina Ochsenbauer-Jambor; Tara G Edmonds; Melina Soares; Gustavo Barbero; Donald N Forthal; Gary Landucci; Connie Chang; Steven W King; Anita Kavlie; Thomas N Denny; Kwan-Ki Hwang; Pojen P Chen; Philip E Thorpe; David C Montefiori; Barton F Haynes Journal: J Exp Med Date: 2010-04-05 Impact factor: 14.307